Our lead asset HERV-K env is:
Training the immune system to stop ALS in its tracks
01
The Challenge
Some forms of ALS are driven by abnormal expression of toxic HERV-K env proteins
02
How it works
Our treatment activates the immune system to generate antibodies that eliminate toxic HERV-K env proteins
03
The Result
Pre-clinical models show vaccine efficacy in reducing neuron damage
04
Clinical Significance
3X
longer survival in ALS patients with naturally high anti-HERV-K env antibodies
